Sullivan & Cromwell Reps Amgen In $1B BioVex Deal
In an announcement Monday, Thousand Oaks, Calif.-based Amgen said that it will pay $425 million when the deal closes following regulatory approval, expected in the first quarter of the year.
In addition, Amgen will make up to $575 million in payments upon the achievement of certain regulatory and sales milestones, the company said.
BioVex is developing a vaccine called OncoVEX,...
To view the full article, register now.